Generalizability of the REDUCE-IT trial to South Asians with cardiovascular disease-Reference-Cited by-同舟云学术

Generalizability of the REDUCE-IT trial to South Asians with cardiovascular disease

Published:2023-02 Issue:2 Volume:4 Page:130-138.e1
ISSN:2666-6340
Container-title:Med
language:en
Short-container-title:Med

Author:

Krishnaraj Aishwarya,Bakbak Ehab,Teoh Hwee,Bhatt Deepak L.,Quan Adrian,Puar Pankaj,Lambotharan Bhaavani,Kirubaharan Aathmika,Firoz Irene N.,Meglis Gus,Yanagawa Bobby,Bari Basel,Kirubaharan Rajaratnam,Vijayaraghavan Ram,Hess David A.,Demchuk Andrew M.,Mancini G. B. John,Tanguay Jean-François,Tardif Jean-Claude,Voisine Pierre,Leiter Lawrence A.,Verma Subodh

Funder

HLS Therapeutics

Publisher

Elsevier BV

Subject

General Medicine

Reference23 articles.

1. Atherosclerotic cardiovascular disease in South Asians in the United States: epidemiology, risk factors, and treatments: a scientific statement from the American heart association;Volgman;Circulation,2018

2. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study;Hippisley-Cox;BMJ,2017

3. Understanding the high prevalence of diabetes in U.S. south Asians compared with four racial/ethnic groups: the MASALA and MESA studies;Kanaya;Diabetes Care,2014

4. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia;Bhatt;N. Engl. J. Med.,2019

5. Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) Meeting Presentation (November 14, 2019);Sharretts,2019

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Vascular Regenerative Cell Deficiencies in South Asian Adults;Journal of the American College of Cardiology;2024-02

2. Global eligibility and cost effectiveness of icosapent ethyl in primary and secondary cardiovascular prevention;Frontiers in Cardiovascular Medicine;2023-08-31